Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence

Simple Summary The widely accepted local therapy in extremity giant cell tumor of bone (GCTB) is surgery, in the form of extended intralesional curettage with adequate disease clearance and retention of the limb, wherever possible. Denosumab is a relevant therapy option for advanced GCTB, to benefit tumor response and surgical down-staging. Most GCTB patients with localized disease can be successfully treated with surgical curettage; patients with primary unresectable lesions or metastases may experience long-term clinical and radiological remission and pain control with denosumab treatment, and in this clinical situation, denosumab is currently the treatment of choice. Abstract (1) Despite the benign nature of the giant cell tumor of bone (GCTB), it shows a local recurrence rate of up to 50% and a chance of malignant transformation. The widely accepted local therapy in extremity GCTB is surgery, in the form of extended intralesional curettage with adequate disease clearance and retention of the limb, wherever possible. Denosumab, a human monoclonal antibody directed against the RANKL and associated inhibition of the RANKL pathway, is a relevant therapy option for advanced GCTB, to benefit tumor response and surgical down-staging. (2) The literature review of patients with GCTB treated with denosumab is performed via PubMed, using suitable keywords from January 2009 to January 2021. (3) Current indications for denosumab use are not definitively clear and unambiguous. Most GCTB patients with localized disease can be successfully treated with surgical curettage, and the role of denosumab in preoperative therapy in this patient population remains unclear. (4) However, patients with primary unresectable lesions or metastases may experience long-term clinical and radiological remission and pain control with denosumab treatment, and in this clinical situation, denosumab is currently the treatment of choice.

[1]  G. Gosheger,et al.  Giant cell tumor of bone: A single center study of 115 cases , 2022, Journal of bone oncology.

[2]  J. Blay,et al.  Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab , 2021, BMC Cancer.

[3]  Yi Yang,et al.  Preoperative Denosumab may increase the Risk of Local Recurrence of Giant-cell Tumor of Bone Treated with Curettage: A Systematic Review and Meta-analysis , 2021, Journal of Cancer.

[4]  J. Mayerson,et al.  Integration of denosumab therapy in the management of giant cell tumors of bone. , 2020, Journal of orthopaedics.

[5]  Zhaoming Ye,et al.  Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls , 2020, Frontiers in Oncology.

[6]  S. Kuwamoto,et al.  Successful Treatment with Denosumab of a Giant Cell Tumor of Bone in the Iliac Bone of an 84-Year-Old Man. , 2020, Yonago acta medica.

[7]  K. van Langevelde,et al.  Radiological findings of denosumab treatment for giant cell tumours of bone , 2020, Skeletal Radiology.

[8]  T. Yayama,et al.  Denosumab Therapy for Giant-cell Tumor of the Lumbar Spine: A Case Report and Immunohistochemical Examination , 2020, Journal of orthopaedic case reports.

[9]  Guo-Chuan Zhang,et al.  Short‐term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone , 2019, Orthopaedic surgery.

[10]  Y. Oda,et al.  Histone H3.3 mutation in giant cell tumor of bone: an update in pathology , 2019, Medical Molecular Morphology.

[11]  J. Blay,et al.  Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. , 2019, The Lancet. Oncology.

[12]  A. Gulia,et al.  Axial giant cell tumor - current standard of practice. , 2019, Journal of clinical orthopaedics and trauma.

[13]  T. Hiraga.  Bone metastasis: Interaction between cancer cells and bone microenvironment. , 2019, Journal of oral biosciences.

[14]  S. Shemesh,et al.  Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature , 2019, Archives of Orthopaedic and Trauma Surgery.

[15]  M. Agarwal,et al.  Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience , 2018, Clinical orthopaedics and related research.

[16]  D. Campanacci,et al.  Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? , 2018, Clinical orthopaedics and related research.

[17]  D. Campanacci,et al.  Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  A. Mavrogenis,et al.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour , 2018, International Orthopaedics.

[19]  K. Ohashi,et al.  Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses , 2018, Histopathology.

[20]  C. Errani,et al.  Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage , 2018, The Journal of bone and joint surgery. American volume.

[21]  M. Jinzaki,et al.  Giant Cell Tumors of the Bone: Changes in Image Features after Denosumab Administration , 2018, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[22]  K. Bradley,et al.  Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab , 2017, Clinical Sarcoma Research.

[23]  I. Krog-Mikkelsen,et al.  Measurement of bone mineral density as an efficacy marker in denosumab treatment of giant cell tumour of bone , 2017, BMJ Case Reports.

[24]  Jacques P. Brown,et al.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. , 2017, The lancet. Diabetes & endocrinology.

[25]  Ryan Folsom,et al.  Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis , 2017, Case reports in orthopedics.

[26]  J. Blay,et al.  Giant cell tumour of bone in the denosumab era. , 2017, European journal of cancer.

[27]  S. Ferrari,et al.  Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? , 2017, European journal of cancer.

[28]  H. Tsuchiya,et al.  Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy , 2017, European Spine Journal.

[29]  M. Ghert,et al.  The Role of Denosumab in the Modern Treatment of Giant Cell Tumor of Bone , 2017, JBJS reviews.

[30]  K. S. Hall,et al.  Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort , 2017, Acta oncologica.

[31]  S. Paydaş,et al.  Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases , 2016, Acta orthopaedica et traumatologica turcica.

[32]  D. Campanacci,et al.  Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series , 2016, World Journal of Surgical Oncology.

[33]  P. Rutkowski,et al.  Denosumab treatment of inoperable or locally advanced giant cell tumor of bone , 2016, Oncology letters.

[34]  David M. Thomas,et al.  Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone , 2016, Clinical Sarcoma Research.

[35]  C. Court,et al.  Interest of Denosumab for the Treatment of Giant-cells Tumors and Aneurysmal Bone Cysts of the Spine. About Nine Cases , 2016, Spine.

[36]  I. Lewis,et al.  UK Guidelines for the Management of Bone Sarcomas , 2010, Sarcoma.

[37]  R. Mohankumar,et al.  Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. , 2016, European journal of cancer.

[38]  J. Mayerson,et al.  Pseudosarcomatous Spindle Cell Proliferation With Osteoid Matrix Mimicking Osteosarcoma: A Distinct Histologic Phenotype in Giant Cell Tumor of Bone Following Denosumab Therapy , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[39]  John B Wojcik,et al.  Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone , 2016, The American journal of surgical pathology.

[40]  A. Ogose,et al.  Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report. , 2016, Oncology letters.

[41]  T. Bocklage,et al.  Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab , 2015, Case reports in medicine.

[42]  A. Ladd,et al.  Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report. , 2015, The Journal of hand surgery.

[43]  T. Ueda,et al.  Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  T. Brodowicz,et al.  Denosumab for the treatment of giant cell tumor of the bone. , 2015, Future oncology.

[45]  Raju Vaishya,et al.  'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab , 2015, Cureus.

[46]  J. Wunder,et al.  Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone , 2015, Annals of Surgical Oncology.

[47]  W. Xu,et al.  Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review , 2015, European Spine Journal.

[48]  G. Farfalli,et al.  A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab , 2015, Clinical orthopaedics and related research.

[49]  J. Reith,et al.  Risk factors for pulmonary metastases from giant cell tumor of bone. , 2015, Journal of Bone and Joint Surgery. American volume.

[50]  G. Matcuk,et al.  Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy , 2015, Skeletal Radiology.

[51]  J. Broto,et al.  Giant cell tumour of bone: new treatments in development , 2015, Clinical and Translational Oncology.

[52]  A. Cleton-Jansen,et al.  Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis , 2014, Virchows Archiv.

[53]  C. Cleeland,et al.  Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study , 2014, Acta oncologica.

[54]  E. Mendel,et al.  Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. , 2014, The spine journal : official journal of the North American Spine Society.

[55]  Robin L. Jones,et al.  The multidisciplinary management of giant cell tumor of bone , 2014, Expert review of anticancer therapy.

[56]  S. Konno,et al.  Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab , 2014, Diagnostic Pathology.

[57]  S. Dry,et al.  Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets , 2014, Pediatric Drugs.

[58]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[59]  David M. Thomas,et al.  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. , 2013, The Lancet. Oncology.

[60]  M. Bishop,et al.  Denosumab Chemotherapy for Recurrent Giant-Cell Tumor of Bone: A Case Report of Neoadjuvant Use Enabling Complete Surgical Resection , 2013, Case reports in oncological medicine.

[61]  J. Manivel,et al.  Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Y. Shih,et al.  Giant cell tumor of the sphenoid bone occurring during pregnancy: Successful tumor extirpation via endoscopic transnasal transsphenoidal surgery , 2013, Clinical Neurology and Neurosurgery.

[63]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[64]  H. Takayanagi,et al.  New insights into osteoclastogenic signaling mechanisms , 2012, Trends in Endocrinology & Metabolism.

[65]  J. Blay,et al.  Giant-cell tumor of bone, anti-RANKL therapy. , 2012, BoneKEy reports.

[66]  David M. Thomas,et al.  Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone , 2012, Clinical Cancer Research.

[67]  M. Balke,et al.  Giant Cell Tumors of the Axial Skeleton , 2012, Sarcoma.

[68]  Jeremiah N. Johnson,et al.  Giant Cell Bone Tumor of the Thoracic Spine Presenting in Late Pregnancy , 2011, Obstetrics and gynecology.

[69]  Richard J. K. Taylor,et al.  RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. , 2011, Bone.

[70]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  F. Sim,et al.  Giant Cell Tumor of Bone: Risk Factors for Recurrence , 2011, Clinical orthopaedics and related research.

[72]  J. Thigpen.  Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma , 2011 .

[73]  David M. Thomas,et al.  Safety of denosumab in giant-cell tumour of bone. , 2010, The Lancet. Oncology.

[74]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[75]  E. McCarthy,et al.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. , 2010, The Iowa orthopaedic journal.

[76]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[77]  P. Hogendoorn,et al.  Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis , 2009, Genes, chromosomes & cancer.

[78]  P. Hogendoorn,et al.  CD33+ CD14− Phenotype Is Characteristic of Multinuclear Osteoclast‐Like Cells in Giant Cell Tumor of Bone , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  P. Picci,et al.  Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone , 2009, Virchows Archiv.

[80]  M. Balke,et al.  Giant cell tumor of bone: treatment and outcome of 214 cases , 2008, Journal of Cancer Research and Clinical Oncology.

[81]  H. Brisse,et al.  Imaging of sacral tumours , 2008, Skeletal Radiology.

[82]  T. Kuklo,et al.  Giant Cell Tumor: A Case Report of Recurrence During Pregnancy , 2005, Spine.

[83]  Y. Iwamoto,et al.  Secondary malignant giant‐cell tumour of bone: molecular abnormalities of p53 and H‐ras gene correlated with malignant transformation , 2001, Histopathology.

[84]  F. Gannon,et al.  From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.